Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Benzinga · 1d ago
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.